Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor
Study Identifier:
18-513
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: andexanet alfa
- Drug: Usual Care
Date
Jun 2019 - May 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: andexanet alfa
- Drug: Usual Care
Date
Jun 2019 - May 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet alfa versus usual care in patients with intracranial hemorrhage anticoagulated with a direct oral FXa anticoagulant
Trial Locations
Location
Status
Location
Research Site
Fort Lauderdale, Florida, United States, 33308
Status
N/A
Location
Research Site
Augusta, Georgia, United States, 30905
Status
N/A
Location
Research Site
Royal Oak, Michigan, United States, 48073
Status
N/A
Location
Research Site
Troy, Michigan, United States, 48085
Status
N/A
Location
Research Site
Albany, New York, United States, 12208
Status
N/A
Location
Research Site
Columbus, Ohio, United States, 43210
Status
N/A